Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Chimeric Therapeutics Ltd. ( (AU:CHM) ).
Chimeric Therapeutics has disclosed that Paul Hopper has ceased to be a substantial shareholder in the company as of 31 December 2025, following the filing of a statutory notice. The change in substantial holding status arises solely from dilution of Hopper’s percentage interest due to a recent share placement, with the company emphasising that there has been no on-market or off-market sale of shares by him, indicating that his absolute shareholding remains unchanged while the company’s expanded capital base has altered ownership proportions.
The most recent analyst rating on (AU:CHM) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Chimeric Therapeutics Ltd. stock, see the AU:CHM Stock Forecast page.
More about Chimeric Therapeutics Ltd.
Chimeric Therapeutics Ltd (ASX: CHM) is an Australia-listed biotechnology company focused on therapeutic development, operating within the life sciences sector. The company is engaged in the research and commercialisation of advanced treatments, positioning itself within the high-growth market for innovative medical therapies.
Technical Sentiment Signal: Sell
Current Market Cap: A$8.22M
See more insights into CHM stock on TipRanks’ Stock Analysis page.